This study is currently recruiting
Description: Learn more about MT-3-01 study, the clinical study that is assessing the efficacy and safety of leriglitazone on the progression of cerebral X-linked Adrenoleukodystrophy (cALD).
Eligibility & Criteria
IRB # : 00382750
Principal Investigator: Dr. Eric Mallack
Eligible Age Range:18 years of age and older
Gender: Male
Diagnosis: Genetic confirmation of X-ALD and have a progressive cALD
Contact Information: Jordan Goodman, Study Coordinator at goodmanj@KennedyKrieger.org or 443-923-2769.